The rise of AI changes many spheres of life, with a projected growth rate of nearly 37% by 2030 — while healthcare is expected to see the most impact from AI use with a long-term adoption rate ...

Several telehealth advocates are coming out in support of the Drug Enforcement Administration’s (DEA) third extension of Covid-19 telehealth flexibilities for the prescribing of controlled ...

Providers across the nation are continuing their work to make value-based care at scale a reality. One of the most recent examples of this comes from Emory Healthcare in Atlanta — on Monday, the ...

Medicine stands at a remarkable crossroads. The explosive growth in specialty drug development marks a new golden age of therapeutic innovation. In 1990 there were just 10 specialty drugs on the ...

Vaginal discomfort is one of the most common reasons women seek healthcare advice, but standard care isn’t always meeting patients’ needs. That’s why Evvy, a vaginal microbiome startup, has ...

Checkpoint inhibitors transformed cancer treatment, bringing to patients immunotherapies now widely used to treat a range of tumors. But there are different types of checkpoints that interact with ...

The overall market for specialty medications has grown dramatically over the past decade, and that trend is expected to continue for at least the next five years. Health systems, patients and ...

My grandfather was a World War II veteran and a Pearl Harbor survivor. While I was fortunate to hear some of his stories, Alzheimer’s robbed me of the chance to learn more about his remarkable ...

Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.

In a typical year, at least 1.7 million adults in America develop sepsis, a life-threatening response to infection. About 30% of severe sepsis patients don’t survive, and up to 50% of survivors ...

Keytruda, a Merck cancer immunotherapy that has become the world’s top-selling medication, is administered as an intravenous infusion over the course of 30 minutes. The pharmaceutical giant now ...

Syndax Pharmaceuticals has won FDA approval for a drug addressing advanced cases of acute leukemia carrying a particular genetic signature that leads to an aggressive form of the disease.